Outcome Of Omalizumab (anti-Ige) Therapy For Severe Persistent Asthma In Inner City Children And Adolescents

被引：0
|
作者：
Ahmad, S. [1 ]
Agrawal, S. [1 ]
Solomon, G. [1 ]
Lee, H. [1 ]
机构：
[1] Suny Downstate Med Ctr, Dept Pediat, Div Pediat Pulmonol, Brooklyn, NY 11203 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2015年 / 191卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4242
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab
    Pacheco-Galvan, Adalberto
    Hinojosa-Macias, Miguel
    Hurtado-Barbudo, Beatriz
    Gonzalez-Cervera, Jesus
    Sueiro-Bendito, Antonio
    MEDICINA CLINICA, 2009, 133 (12): : 460 - 463
  • [42] Efficacy Of The Anti-Ige Monoclonal Antibody Omalizumab In Patients With Severe Asthma Complicated With Eosinophilic Otitis Media
    Tagaya, E.
    Mizobuchi, R.
    Kubo, A.
    Hara, K.
    Takeyama, K.
    Kondo, M.
    Tamaoki, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [43] Successful treatment with anti-IgE (omalizumab) in child with severe atopic dermatitis
    Yilmaz, Arik E.
    Sackesen, C.
    Buyuktiryaki, B.
    Cavkaytar, O.
    Yavuz, S. T.
    Sahiner, U. M.
    Sekerel, B.
    Tuncer, A.
    ALLERGY, 2013, 68 : 617 - 617
  • [44] Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy
    Kariyawasarn, Harsha H.
    James, Louisa K.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 5483 - 5494
  • [45] Severe asthma: anti-IgE or anti-IL-5?
    Papathanassiou, Evgenia
    Loukides, Stelios
    Bakakos, Petros
    EUROPEAN CLINICAL RESPIRATORY JOURNAL, 2016, 3
  • [46] Anti-IgE monoclonal antibody (omalizumab) treatment increases blood glucose levels in severe persistent allergic asthma patients with type 2 diabetes
    Yalcin, A. D.
    Cilli, A.
    Gorczynski, R.
    Bisgin, A.
    Strauss, L.
    ALLERGY, 2013, 68 : 364 - 364
  • [47] IgE and non-IgE mediated reaction following anti-IgE therapy for severe asthma: a therapeutic dilemma
    Ali, S. B.
    Jodie, T.
    Lucas, A.
    Hollingsworth, P. N.
    Lucas, M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 1121 - 1121
  • [48] No reduction in BMI in severe asthma patients after one year of omalizumab (anti-IgE) therapy despite reduced systemic steroid exposure
    Long, D.
    McGeoghegan, C.
    Ryan, D.
    Thong, L.
    Costello, R. W.
    Ryan, D. M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 : S432 - S432
  • [49] No reduction in BMI in severe asthma patients after one year of omalizumab (anti-IgE) therapy despite reduced systemic steroid exposure
    Long, D.
    McGeoghegan, C.
    Ryan, D.
    Thong, L.
    Costello, R. W.
    Ryan, D. M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 (SUPPL 10) : S432 - S432
  • [50] A case of recurrent anaphylaxis with asthma treated with anti-IgE monoclonal antibody omalizumab
    Ernesti, I
    Indinnimeo, L.
    Schiavi, L.
    De Vitori, V.
    Melengu, T.
    Bardanzellu, F.
    Duse, M.
    ALLERGY, 2013, 68 : 363 - 363
12345